Thrombotic thrombocytopenic purpura - Then and now

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and formation of microthrombi in several organs. The disease may manifest once in a lifetime or may relapse after complete recovery of the initial episode; in these recurrent cases, death or neurological sequelae are common final outcomes. Accumulation of unusually large (UL) von Willebrand factor (VWF) multimers was described in the plasma of patients with TTP. Such ULVWF multimers are synthesized in endothelial cells and megakaryocytes and are secreted into the blood upon stimulation. However, in healthy individuals ULVWF multimers do not normally circulate because they are rapidly reduced into smaller multimers soon after their secretion due to cleavage by a plasma metalloprotease, ADAMTS13. Deficiency of ADAMTS13 has been reported consistently in patients with TTP. Such defect may be constitutive, due to homozygous or double heterozygous mutations in the corresponding gene, or acquired, due to the presence of circulating inhibitory antibodies. It follows that in TTP patients, the absent or severely depressed plasma ADAMTS13 activity limits the cleavage of ULVWF multimers, which remain anchored to the endothelial cells in long strings. Particularly under conditions of high shear stress, the multimers may promote the adhesion of circulating platelets, initiating thrombus formation. The clinical implications of these findings to the diagnosis and treatment of TTP are discussed.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalSeminars in Thrombosis and Hemostasis
Volume32
Issue number2
Publication statusPublished - Mar 2006

Fingerprint

Thrombotic Thrombocytopenic Purpura
Endothelial Cells
Megakaryocytes
Hemolytic Anemia
von Willebrand Factor
Metalloproteases
Thrombocytopenia
Thrombosis
Blood Platelets
Recurrence
Mutation
Antibodies
Genes

Keywords

  • ADAMTS13
  • Endothelial damage
  • Hemolytic uremic syndrome
  • Thrombotic thrombocytopenic purpura
  • Von Willebrand factor

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombotic thrombocytopenic purpura - Then and now. / Galbusera, Miriam; Noris, Marina; Remuzzi, Giuseppe.

In: Seminars in Thrombosis and Hemostasis, Vol. 32, No. 2, 03.2006, p. 81-89.

Research output: Contribution to journalArticle

@article{91957f70426c4a7f851e971fece0fe1f,
title = "Thrombotic thrombocytopenic purpura - Then and now",
abstract = "Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and formation of microthrombi in several organs. The disease may manifest once in a lifetime or may relapse after complete recovery of the initial episode; in these recurrent cases, death or neurological sequelae are common final outcomes. Accumulation of unusually large (UL) von Willebrand factor (VWF) multimers was described in the plasma of patients with TTP. Such ULVWF multimers are synthesized in endothelial cells and megakaryocytes and are secreted into the blood upon stimulation. However, in healthy individuals ULVWF multimers do not normally circulate because they are rapidly reduced into smaller multimers soon after their secretion due to cleavage by a plasma metalloprotease, ADAMTS13. Deficiency of ADAMTS13 has been reported consistently in patients with TTP. Such defect may be constitutive, due to homozygous or double heterozygous mutations in the corresponding gene, or acquired, due to the presence of circulating inhibitory antibodies. It follows that in TTP patients, the absent or severely depressed plasma ADAMTS13 activity limits the cleavage of ULVWF multimers, which remain anchored to the endothelial cells in long strings. Particularly under conditions of high shear stress, the multimers may promote the adhesion of circulating platelets, initiating thrombus formation. The clinical implications of these findings to the diagnosis and treatment of TTP are discussed.",
keywords = "ADAMTS13, Endothelial damage, Hemolytic uremic syndrome, Thrombotic thrombocytopenic purpura, Von Willebrand factor",
author = "Miriam Galbusera and Marina Noris and Giuseppe Remuzzi",
year = "2006",
month = "3",
language = "English",
volume = "32",
pages = "81--89",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Thrombotic thrombocytopenic purpura - Then and now

AU - Galbusera, Miriam

AU - Noris, Marina

AU - Remuzzi, Giuseppe

PY - 2006/3

Y1 - 2006/3

N2 - Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and formation of microthrombi in several organs. The disease may manifest once in a lifetime or may relapse after complete recovery of the initial episode; in these recurrent cases, death or neurological sequelae are common final outcomes. Accumulation of unusually large (UL) von Willebrand factor (VWF) multimers was described in the plasma of patients with TTP. Such ULVWF multimers are synthesized in endothelial cells and megakaryocytes and are secreted into the blood upon stimulation. However, in healthy individuals ULVWF multimers do not normally circulate because they are rapidly reduced into smaller multimers soon after their secretion due to cleavage by a plasma metalloprotease, ADAMTS13. Deficiency of ADAMTS13 has been reported consistently in patients with TTP. Such defect may be constitutive, due to homozygous or double heterozygous mutations in the corresponding gene, or acquired, due to the presence of circulating inhibitory antibodies. It follows that in TTP patients, the absent or severely depressed plasma ADAMTS13 activity limits the cleavage of ULVWF multimers, which remain anchored to the endothelial cells in long strings. Particularly under conditions of high shear stress, the multimers may promote the adhesion of circulating platelets, initiating thrombus formation. The clinical implications of these findings to the diagnosis and treatment of TTP are discussed.

AB - Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and formation of microthrombi in several organs. The disease may manifest once in a lifetime or may relapse after complete recovery of the initial episode; in these recurrent cases, death or neurological sequelae are common final outcomes. Accumulation of unusually large (UL) von Willebrand factor (VWF) multimers was described in the plasma of patients with TTP. Such ULVWF multimers are synthesized in endothelial cells and megakaryocytes and are secreted into the blood upon stimulation. However, in healthy individuals ULVWF multimers do not normally circulate because they are rapidly reduced into smaller multimers soon after their secretion due to cleavage by a plasma metalloprotease, ADAMTS13. Deficiency of ADAMTS13 has been reported consistently in patients with TTP. Such defect may be constitutive, due to homozygous or double heterozygous mutations in the corresponding gene, or acquired, due to the presence of circulating inhibitory antibodies. It follows that in TTP patients, the absent or severely depressed plasma ADAMTS13 activity limits the cleavage of ULVWF multimers, which remain anchored to the endothelial cells in long strings. Particularly under conditions of high shear stress, the multimers may promote the adhesion of circulating platelets, initiating thrombus formation. The clinical implications of these findings to the diagnosis and treatment of TTP are discussed.

KW - ADAMTS13

KW - Endothelial damage

KW - Hemolytic uremic syndrome

KW - Thrombotic thrombocytopenic purpura

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=33645574296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645574296&partnerID=8YFLogxK

M3 - Article

C2 - 16575682

AN - SCOPUS:33645574296

VL - 32

SP - 81

EP - 89

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 2

ER -